A Phase 1b/2 Study of AST-008 Combined With Pembrolizumab in Patients With Advanced Solid Tumors

Conditions:   Advanced or Metastatic Solid Tumors;   Advanced or Metastatic Melanoma;   Advanced or Metastatic Head and Neck Squamous Cell Carcinoma;   Advanced or Metastatic Cutaneous Squamous Cell Carcinoma;   Advanced or Metastatic Merkel Cell Carcinoma
Interventions:   Drug: AST-008;   Biological: Pembrolizumab
Sponsor:   Exicure, Inc.
Not yet recruiting

https://ift.tt/2ORkeu8